ACAD - NASDAQ

ACADIA Pharmaceuticals Inc.

ACAD·NASDAQ

$21.43

+2.2%

HealthcareBiotechnology

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$3.67B

EPS2.3200

P/E Ratio11.57

Earnings Date08/05/2026

1.56B

Assets

32%

3Y+166.0%

5Y+100.0%

10Y+179.0%

336.81M

Total Liabilities

-26%

3Y+80.0%

5Y+116.0%

10Y+688.0%

1.23B

Total Equity

67%

3Y+207.0%

5Y+96.0%

10Y+137.0%

ACADIA Pharmaceuticals Inc. Funding & Solvency Profile

ACAD · NASDAQ

Current Assets

Cash & Cash Equivalents177.69M

Net Receivables148.23M

Inventory34.67M

Other Current Assets0.00

Total Current Assets1 B

Non-Current Assets

Property, Plant & Equipment54.87M

Goodwill & Intangible Assets108.89M

Long-Term Investments7.84M

Other Non-Current Assets80.60M

Total Non-Current Assets143 M

Total Assets

1.56B

Financial Health Analysis

Current Ratio

3.83x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.27x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

785 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

68% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

ACADIA Pharmaceuticals Inc. Balance Sheet

ACAD • NASDAQ

ACADIA Pharmaceuticals Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009	Dec 2008	Dec 2007	Dec 2006
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	177.7M	319.6M	188.7M	114.8M	147.4M	326M	189.7M	134.8M	69.4M	163.6M	102.1M	61.9M	11.7M	57.9M	6.9M	6.8M	18.1M	21.2M	17M	15.5M
Short-Term Investments	642M	436.4M	250.2M	302M	373.3M	305.9M	507.7M	338.8M	271.9M	365.4M	113M	260.6M	174.1M	50.1M	24.2M	30.2M	28.9M	38.9M	109.9M	67.8M
Cash & Short-Term Investments	819.7M	756M	438.9M	416.8M	520.7M	632M	697.4M	473.5M	341.3M	529M	215.1M	322.5M	185.8M	108M	31M	37.1M	47.1M	60.1M	126.9M	83.3M
Net Receivables	148.2M	104.7M	102.4M	63.1M	65.3M	50.3M	37.9M	27.8M	18.4M	7.1M	1.6M	964K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accounts Receivables	121.5M	98.7M	98.3M	62.2M	64.4M	48.2M	35.8M	26.1M	17.3M	5.9M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Receivables	26.8M	6M	4.1M	885K	978K	2M	2.1M	1.7M	1.1M	1.2M	1.6M	964K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Inventory	34.7M	21.9M	35.8M	6.6M	7.9M	9.7M	6.3M	4.1M	5.2M	4.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Prepaids	59.5M	55.7M	39.1M	21.4M	23.9M	25.7M	18.6M	20.7M	8.5M	7.5M	2.2M	1.2M	1.8M	581K	901K	762K	1.4M	2.3M	4.4M	2.5M
Other Current Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.6M	581K	0.0	0.0	0.0	0.0	0.0	0.0
Total Current Assets	1.1B	938.3M	616.1M	507.9M	617.8M	717.6M	760.3M	526.1M	373.5M	547.9M	219M	324.6M	188.4M	108.5M	31.9M	37.8M	48.5M	62.4M	131.3M	85.8M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	54.9M	50.8M	56.5M	61.6M	66.3M	56.4M	12.7M	3.3M	2.7M	3.1M	2.2M	553K	579K	42K	151K	426K	1.1M	2.1M	3M	3.5M
Intangible Assets	108.9M	119.8M	65.5M	0.0	0.0	1.1M	2.6M	4.1M	5.5M	7M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Goodwill & Intangible Assets	108.9M	119.8M	65.5M	0.0	0.0	1.1M	2.6M	4.1M	5.5M	7M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Long-Term Investments	7.8M	0.0	5.8M	13M	0.0	7.1M	7.1M	4.8M	2.5M	2.4M	375K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Assets	249.9M	0.0	0.0	0.0	0.0	0.0	0.0	-4.8M	-2.5M	-2.4M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	80.6M	78.9M	5.1M	5.3M	16M	378K	557K	6.7M	2.8M	3.2M	329K	287K	179K	-42K	14K	119K	145K	192K	283K	256K
Total Non-Current Assets	502.1M	249.4M	132.8M	79.9M	82.3M	65M	22.9M	14.1M	11M	13.3M	2.9M	840K	758K	42K	165K	545K	1.2M	2.3M	3.3M	3.8M
Total Assets	1.6B	1.2B	749M	587.8M	700.1M	782.6M	783.2M	540.2M	384.5M	561.2M	221.9M	325.5M	189.1M	108.6M	32.1M	38.4M	49.7M	64.7M	134.6M	89.5M
LIABILITIES
CURRENT LIABILITIES
Total Payables	11.2M	28.2M	19.1M	12.7M	6.9M	8.5M	7.2M	3.2M	8.8M	3.9M	1.7M	2M	372K	1.4M	2M	2M	2.9M	2.3M	2.6M	3.4M
Accounts Payable	10.9M	16.2M	17.5M	12.7M	6.9M	8.5M	7.2M	3.2M	8.8M	3.9M	1.7M	2M	372K	1.4M	2M	2M	2.9M	2.3M	2.6M	3.4M
Other Payables	304K	12M	1.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accrued Expenses	0.0	320.2M	133.4M	54.1M	55M	39.9M	32.4M	22.9M	18.9M	14.4M	5.7M	4.2M	1.9M	413K	2.8M	3.2M	5.4M	7.5M	15M	13.5M
Short Term Debt	11.6M	0.0	9.4M	0.0	0.0	5.1M	3.4M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	32K	78K	365K	795K	978K	996K
Capital Lease Obligations (Current)	0.0	10M	0.0	9.3M	8.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Payables	0.0	12M	1.6M	377K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.6M	0.0	0.0	55K	434K	669K	690K	6M	438K	707K	2.7M
Other Current Liabilities	254.6M	36.6M	92.3M	49.5M	25.9M	52.5M	31.8M	33.5M	21.4M	21.6M	14.5M	9.7M	4.7M	3.7M	679K	0.0	0.0	0.0	0.0	0.0
Total Current Liabilities	277.1M	394.9M	254.3M	125.6M	96.1M	106M	74.8M	59.6M	49M	42.6M	21.9M	15.8M	7M	5.9M	6.2M	6M	14.7M	11.1M	19.3M	20.5M
NON-CURRENT LIABILITIES
Long Term Debt	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	32K	98K	430K	1.2M	1.4M
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.6M	2.6M	22.6M	0.0	0.0	0.0
Other Non-Current Liabilities	19.1M	18.1M	15.1M	9.1M	7M	5.2M	2.9M	1.6M	191K	157K	232K	135K	8K	0.0	0.0	92K	182K	204K	207K	472K
Total Non-Current Liabilities	59.7M	60.1M	62.9M	61.8M	63.2M	49.6M	9.2M	1.6M	191K	157K	232K	135K	8K	17.7M	2.6M	2.7M	22.9M	634K	1.4M	1.9M
Capital Lease Obligations	40.6M	52M	47.8M	62M	64.4M	44.5M	6.4M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	336.8M	455M	317.2M	187.4M	159.2M	155.6M	84M	61.1M	49.2M	42.7M	22.1M	16M	7M	23.6M	8.8M	8.7M	37.6M	11.7M	20.7M	22.4M
SHAREHOLDERS' EQUITY
Common Stock	16K	16K	16K	16K	16K	16K	15K	14K	12K	12K	10K	10K	9K	7K	5K	4K	4K	4K	4K	3K
Additional Paid-In Capital	3B	2.9B	2.9B	2.8B	2.7B	2.6B	2.4B	1.9B	1.6B	1.5B	862.3M	807.6M	587.7M	452.7M	370.2M	353.3M	350.9M	346.8M	343.3M	240.4M
Retained Earnings	-1.8B	-2.2B	-2.4B	-2.4B	-2.2B	-2B	-1.7B	-1.5B	-1.2B	-934M	-662.6M	-498.1M	-405.7M	-367.7M	-346.9M	-324.1M	-339.2M	-294.1M	-229.9M	-173.5M
Accumulated Other Comprehensive Income/Loss	1.4M	292K	24K	-975K	-192K	36K	297K	-372K	-399K	106K	11K	-9K	48K	4K	9K	512K	483K	273K	493K	176K
Total Stockholders' Equity	1.2B	732.8M	431.8M	400.4M	540.9M	627M	699.1M	479.1M	335.3M	518.4M	199.8M	309.5M	182.1M	85M	23.4M	29.7M	12.1M	53M	113.9M	67.2M
Total Equity	1.2B	732.8M	431.8M	400.4M	540.9M	627M	699.1M	479.1M	335.3M	518.4M	199.8M	309.5M	182.1M	85M	23.4M	29.7M	12.1M	53M	113.9M	67.2M
SUMMARY
Total Liabilities & Equity	1.6B	1.2B	749M	587.8M	700.1M	782.6M	783.2M	540.2M	384.5M	561.2M	221.9M	325.5M	189.1M	108.6M	32.1M	38.4M	49.7M	64.7M	134.6M	89.5M
Total Investments	649.8M	436.4M	256M	314.9M	373.3M	313M	514.8M	343.6M	274.4M	367.8M	113M	260.6M	174.1M	50.1M	24.2M	30.2M	28.9M	38.9M	109.9M	67.8M
Total Debt	52.2M	52M	57.2M	62M	64.4M	49.5M	9.8M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	32K	110K	463K	1.2M	2.1M	2.4M
Net Debt	-125.5M	-267.6M	-131.5M	-52.8M	-83M	-276.5M	-179.9M	-134.8M	-69.4M	-163.6M	-102.1M	-61.9M	-11.7M	-57.9M	-6.9M	-6.7M	-17.7M	-19.9M	-14.9M	-13.1M
Shares Outstanding	169,166,967	169,166,967	169,166,967	169,166,967	169,166,967	169,166,967	169,166,967	169,166,967	169,166,967	169,166,967	169,166,967	169,166,967	169,166,967	169,166,967	169,166,967	169,166,967	169,166,967	169,166,967	169,166,967	169,166,967

SEC Filings

ACAD - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 29, 2026	May 29, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 07, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 06, 2026	May 06, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 01, 2026	April 27, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 24, 2026	May 29, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 05, 2026	March 03, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 26, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 25, 2026	February 25, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 13, 2026	January 13, 2026	2026	View Filing
10-Q 10-Q 2025 Q3 Q3	November 06, 2025	September 30, 2025	2025	View Filing

Showing 1 to 10 of 365 filings

Related Guides

Blog Categories

Continue your ACAD research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.